For example, it was shown that tumor‐specific Hsp90 inhibitors disrupt BCR signaling at various steps, thus creating a situation where combination with BTK inhibitors yields synergistic killing of ABC‐DLBCL cells.217. This evidence concerns the gene BCR and diffuse large B-cell lymphoma.